Hanna Bandos1, Joy Melnikow1, Donna R Rivera1, Sandra M Swain1, Keren Sturtz1, Louis Fehrenbacher1, James L Wade1, Adam M Brufsky1, Thomas B Julian1, Richard G Margolese1, Edward C McCarron1, Patricia A Ganz1. 1. NRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.
Abstract
Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL). Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer. The AC→T group had a higher cumulative dose of T. PN was one of the symptoms assessed in a QOL substudy. Statistical methods included simple and mixed ordinal logistic regression and general linear models. All statistical tests were two-sided. Results: Of 1512 patients, 41.9% reported PN two years after treatment initiation. Treatment with AT and ACT was associated with less severe long-term PN compared with AC→T (odds ratio [OR] = 0.45, 95% confidence interval [CI] = 0.35 to 0.58; OR = 0.59, 95% CI = 0.46 to 0.75). Preexisting PN, older age, obesity, mastectomy, and greater number of positive nodes were also associated with higher risk of long-term PN. Patients who reported worse PN symptoms at 24 months had statistically significantly worse QOL (Ptrend < .001). Conclusions: The administration of docetaxel is associated with long-term PN. The lower rate of long-term PN in AT and ACT patients might be an important consideration in supporting choosing these therapies for individuals with preexisting neuropathic symptoms or other risk factors for neuropathy.
RCT Entities:
Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL). Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer. The AC→T group had a higher cumulative dose of T. PN was one of the symptoms assessed in a QOL substudy. Statistical methods included simple and mixed ordinal logistic regression and general linear models. All statistical tests were two-sided. Results: Of 1512 patients, 41.9% reported PN two years after treatment initiation. Treatment with AT and ACT was associated with less severe long-term PN compared with AC→T (odds ratio [OR] = 0.45, 95% confidence interval [CI] = 0.35 to 0.58; OR = 0.59, 95% CI = 0.46 to 0.75). Preexisting PN, older age, obesity, mastectomy, and greater number of positive nodes were also associated with higher risk of long-term PN. Patients who reported worse PN symptoms at 24 months had statistically significantly worse QOL (Ptrend < .001). Conclusions: The administration of docetaxel is associated with long-term PN. The lower rate of long-term PN in AT and ACT patients might be an important consideration in supporting choosing these therapies for individuals with preexisting neuropathic symptoms or other risk factors for neuropathy.
Authors: Donna R Rivera; Patricia A Ganz; Meghan S Weyrich; Hanna Bandos; Joy Melnikow Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2010-12-03 Impact factor: 4.872
Authors: Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse Journal: Support Care Cancer Date: 2014-05-01 Impact factor: 3.603
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Daniel L Hertz; Kelley M Kidwell; Kiran Vangipuram; Feng Li; Manjunath P Pai; Monika Burness; Jennifer J Griggs; Anne F Schott; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry Journal: Clin Cancer Res Date: 2018-04-27 Impact factor: 12.531
Authors: Donna R Rivera; Patricia A Ganz; Meghan S Weyrich; Hanna Bandos; Joy Melnikow Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Jose F Moruno-Manchon; Ndidi-Ese Uzor; Shelli R Kesler; Jeffrey S Wefel; Debra M Townley; Archana Sidalaghatta Nagaraja; Sunila Pradeep; Lingegowda S Mangala; Anil K Sood; Andrey S Tsvetkov Journal: Mol Cell Neurosci Date: 2017-11-24 Impact factor: 4.314
Authors: Hannah C Timmins; Tiffany Li; Terry Trinh; Matthew C Kiernan; Michelle Harrison; Frances Boyle; Michael Friedlander; David Goldstein; Susanna B Park Journal: Oncologist Date: 2021-02-10
Authors: Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss Journal: Oncologist Date: 2018-12-14
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14
Authors: Yongzhen Chen; Fang Fang; Kelley M Kidwell; Kiran Vangipuram; Lauren A Marcath; Christina L Gersch; James M Rae; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry; Andreas S Beutler; Daniel L Hertz Journal: Pharmacogenomics Date: 2020-07-23 Impact factor: 2.533
Authors: W Iris Zhi; Patricia Chen; Alice Kwon; Connie Chen; Steven E Harte; Lauren Piulson; Susan Li; Sujata Patil; Jun J Mao; Ting Bao Journal: Breast Cancer Res Treat Date: 2019-08-27 Impact factor: 4.872
Authors: Susan Storey; Andrea Cohee; Diane Von Ah; Eric Vachon; Noah R Zanville; Patrick O Monahan; Timothy E Stump; Victoria L Champion Journal: J Patient Cent Res Rev Date: 2020-10-23
Authors: Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel Journal: Oncologist Date: 2019-10-14